Liposomes in drug delivery: Progress and limitations

International Journal of Pharmaceutics

Volumn 154, Issue 2, 1997, Pages 123-140

  Sharma, Amarnath ^a   Sharma, Uma S ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Amphotericin B; Doxorubicin; Drug delivery; Liposome

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANNAMYCIN; ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; IMMUNOLIPOSOME; LIPOSOME; MURAMYL DIPEPTIDE; NYSTATIN; PACLITAXEL; PROSTAGLANDIN E1; RETINOIC ACID; UNCLASSIFIED DRUG; VACCINE; VENTUS;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; GENE THERAPY; HUMAN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; SURFACE PROPERTY;

EID: 0030795298     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00135-X     Document Type: Review

References (72)

1. Ahmad, I., Longenecker, M., Samuel, J., Allen, T.M., 1993. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53, 1484-1488.
2. Allen, T.M., Chonn, A., 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223, 42-46.
3. Allen, T.M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A., 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066, 29-36.
4. Allen, T.M., Mehra, T., Hansen, C., Chin, Y.C., 1992. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 52, 2431-2439.
5. Allen, T.M., Ryan, J.L., Papahadjopoulos, D., 1985. Gangliosides reduce leakage of aqueous-space markers from liposomes in the presence of human plasma. Biochim. Biophys. Acta 818, 205-210.
6. Allison, A.C., Gregoriadis, G., 1974. Liposomes as immunological adjuvants. Nature 252, 252.
7. Alving, C.R., 1991. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 140, 1-13.
8. Bangham, A.D., Horne, R.W., 1964. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 8, 660-668.
9. Binder, J., Mishina, E.V., Jusko, W.J., Kupiec-Weglinski, J.W., 1994. Prolongation of cardiac allograft survival in rats by liposome-encapsulated methylprednisolone. Transplantation 58, 633-635.
10. Clerc, S., Barenholz, Y., 1995. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim. Biophys. Acta 1240, 257-265.
11. Crystal, R.G., 1995. Transfer of genes to humans: early lessons and obstacles to success. Science 270, 404-410.
12. Deamer, D. and Uster, P., Liposome preparation methods and monitoring liposome fusion. In: Baserga, R., Croce, C. and Royeza, G. (Eds.), Introduction of Macromolecules into viable Mammalian Cells, Alan R. Liss, New York, 1980, pp. 205-220.
13. de Marie, S., Janknegt, R., Bakker-Woudenberg, I.A.J.M., 1994. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33, 907-916.
14. Dedrick, R.L., Myers, C.E., Bungay, P.M., DeVita, V.T. Jr., 1978. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1-11.
15. Ehrlich, P. The relations existing between chemical constitution, distribution and pharmacological action. In Ehrlich, P. (Ed.), Collected Studies on Immunity, Vol. 2, Wiley, New York, 1906, pp. 404-443.
16. Emanuel, N., Kedar, E., Bolotin, E.M., Smorodinsky, N.I., Barenholz, Y., 1996. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes. Pharm. Res. 13, 352-359.
17. Felgner, J.H., Kumar, R., Sridhar, C.N., Wheeler, C.J., Tsai, Y.J., Border, R., Ramsey, P., Martin, M., Felgner, P.L., 1994. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269, 2550-2561.
18. Felgner, P.L., Gadek, T.R., Holm, M., Roman, R., Chan, H.W., Wenz, M., Northrop, J.P., Ringold, G.M., Danielsen, M., 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84, 7413-7417.
19. Felgner, P.L., Ringold, G.M., 1989. Cationic liposome-mediated transfection.. Nature 377, 387-388.
20. Felgner, P.L., Zangg, R.H., Norman, J.A., 1995. Synthetic recombinant DNA delivery for cancer therapeutics. Cancer Gene Ther. 2, 61-65.
21. Forssen, E.A., Male-Brune, R., Adler-Moore, J.P., Lee, M.J., Schmidt, P.G., Krasieva, T.B., Shimizu, S., Tromberg, B.J., 1996. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56, 2066-2075.
22. Forssen, E.A., Tokes, Z.A., 1983. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat. Rep. 67, 481-484.
23. Gabizon, A., Papahadjopoulos, D., 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85, 6949-6953.
24. Gabizon, A., Price, D.C., Huberty, J., Bresalier, R.S., Papahadjopoulos, D., 1990. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 50, 6371-6378.
25. Gabizon, A.A., Liposomal anthracyclines. Hematology - Oncology Clinics of North America, 8 (1994) 431-450.
26. Gao, X., Huang, L., 1995. Cationic liposome-mediated gene transfer. Gene Ther. 2, 710-722.
27. Gregoriadis, G., 1995. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 13, 527-537.
28. Gregoriadis, G., 1990. Immunological adjuvants: a role for liposomes. Immunol Today 11, 89-97.
29. Gregoriadis, G., Florence, A.T., 1993. Liposomes in drug delivery: Clinical, diagnostic and ophthalmic potential. Drugs 45, 15-28.
30. Gregoriadis, G., Panagiotidi, C., 1989. Immunoadjuvant action of liposomes: comparison with other adjuvants. Immunol. Lett. 20, 237-240.
31. Gruner, S.M., Lenk, R.P., Janoff, A.S., Ostro, M.J., 1985. Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles. Biochemistry 24, 2833-2842.
32. Harashima, H., Sakata, K., Funato, K., Kiwada, H., 1994. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res. 11, 402-406.
33. Hay, R.J., 1994. Liposomal amphotericin B, AmBisome. J. Infection 28, 35-43.
34. Heath, T.D., Brown, C.S., 1989. Liposome dependent delivery of N-(phosphonacetyl)-L-aspartic acid to cells in vitro. J. Liposome Res. 1, 303-317.
35. Hong, K., Zheng, W., Baker, A., Papahadjopoulos, D., 1997. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjuates for efficient in vivo gene delivery. FEBS Lett. 400, 233-237.
36. Juliano, R.L., Grant, C.W., Barber, K.R., Kalp, M.A., 1987. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31, 1-11.
37. Kersten, G.F.A., Crommelin, D.J.A., 1995. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta 1241, 117-138.
38. Killion, J.J., Fidler, I.J., 1994. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. Immunomethods 4, 273-279.
39. Klibanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P., Huang, L., 1991. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1062, 142-148.
40. Kraaijeveld, C.A., Schilham, M., Jansen, J., Benaissa-Trouw, B., Harmsen, M., van Houte, A.J., Snippe, H., 1984. The effect of liposomal charge on the neutralizing antibody response against inactivated encephalomyocarditis and Semliki Forest Viruses. Clin. Exp. Immunol. 56, 509-514.
41. Lasic, D.D., Martin, F.J., Gabizon, A., Huang, S.K., Papahadjopoulos, D., 1991. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070, 187-192.
42. Lasic, D.D., Papahadjopoulos, D., 1995. Liposomes revisited. Science 267, 1275-1276.
43. Markman, M., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadones, L., Lewis, J.L., 1989. Intraperitoneal therapy in the management of ovarian cancer. Yale J. Biol. Med. 62, 393-403.
44. Martin, F.J., Pharmaceutical manufacturing of liposomes. In: Tyle, P. (Ed.), Specialized Drug Delivery System: Manufacturing and Production Technology, Marcell Dekker, New York, 1990, pp. 267-316.
45. Mayer, L.D., Bally, M.B., Cullis, P.R., 1986. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 857, 123-126.
46. Mayer, L.D., Tai, L.C., Bally, M.B., Mitilenes, G.N., Ginsberg, R.S., Cullis, P.R., 1990. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta 1025, 143-151.
47. Mayhew, E.G., Lasic, D., Babbar, S., Martin, F.J., 1992. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int. J. Cancer 51, 302-309.
48. Nabel, G.J., Chang, A.E., Hersh, E.M., Vogeizang, N.J., Rubin, J., Silver, H., Stah, S., Schreiber, A.B., 1995. Combined experience from Phase I studies with Allovectin-7, a direct gene transfer immunotherapeutic, in patients with metastatic solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14, A582.
49. New, R.R.C., Preparation of liposomes. In: New, R.R.C. (Ed.), Lipsomes: a practical approach, IRL Press, Oxford, 1990, pp. 33-104.
50. Ng, T.T., Denning, D.W., 1995. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch. Intern. Med. 155, 1093-1098.
51. Ohsawa, T., Miura, H., Harada, K., 1984. A novel method for preparing liposome with a high capacity to encapsulate proteinous drugs: freeze-drying method. Chem. Pharm. Bull. 32, 2442-2445.
52. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C., Martin, F.J., 1991. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88, 11460-11464.
53. Papahadjopoulos, D., Watkins, J.C., 1967. Phospholipid model membranes. II. Permeability properties of hydrated liquid crystals. Biochim. Biophys. Acta 135, 639-652.
54. Sharma, A., Liposomal delivery of antineoplastic drugs: preparation, characterization and antitumor activity of liposomal drug formulations. Ph.D. Thesis, State University of New York at Buffalo, 1994.
55. Sharma, A., Mayhew, E., Bolcsak, L., Cavanaugh, C., Harmon, P., Janoff, A., Bernacki, R.J., 1997. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer. 71, 103-107.
56. Sharma, A., Mayhew, E., Straubinger, R.M., 1993. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 53, 5877-5881.
57. Sharma, A., Sharma, U.S., Straubinger, R.M., 1996. Paclitaxel-liposomes for local treatment of intraperitoneal P388 leukemia. Cancer lett. 107, 265-272.
58. Sharma, A., Straubinger, N.L., Straubinger, R.M., 1993a. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers. Pharm. Res. 10, 1434-1441.
59. Sharma, A., Straubinger, R.M., 1994. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 11, 889-896.
60. Sharma, A., Straubinger, R.M., Ojima, I., Bernacki, R.J., 1995. Antitumor Efficacy Of Taxane Liposomes On a Human Ovarian Tumor Xenograft In Nude Athymic Mice. J. Pharm. Sci. 84, 1400-1404.
61. Straubinger, R., Sharma, A., Murray, M., Mayhew, E., 1993. Novel taxol formulations: taxol containing liposomes. J. Natl. Cancer Inst. Monograph 15, 69-78.
62. Straubinger, R., Sharma, A., Mayhew, E., Taxol Formulation. US Patent 5415869, 16 May, 1995.
63. Straubinger, R.M., Hong, K., Friend, D.S., Papahadjopoulos, D., 1983. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell 32, 1069-1079.
64. Szoka, F. Jr., Papahadjopoulos, D., 1980. Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann. Rev. Biophys. Bioeng. 9, 467-508.
65. Szoka, F.C., Liposomal drug delivery: current status and future prospects. In: Wilschut, J., Hoekstra, D. (Eds.), Membrane Fusion, Marcel Dekker, New York, 1991, pp. 845-890.
66. Torchilin, V.P., Narula, J., Halpern, E., Khaw, B.A., 1996. Poly(ethylene glycol)-coated anti-cardiac anti-cardiac myosin immunoliposomes - factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta 1279, 75-83.
67. Vingerhoeds, M.H., Steerenberg, P.A., Hendriks, J.J.G.S., Crommelin, D.J.A., Storm, G., 1996. Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti-diphtheria toxin antibodies. FEBS Lett. 395, 245-250.
68. White, J.C., Hines, L.H., 1984. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis. Cancer Res. 44, 507-513.
69. Yasuda, T., Dancey, G.F., Kinsky, S.C., 1977. Immunogenicity of liposomal model membranes in mice: dependence on phospholipid composition. Proc. Natl. Acad. Sci. USA 74, 1234-1236.
70. Yuan, F., Leunig, M., Huang, S.K., Berk, D.A., Papahadjopoulos, D., Jain, R.K., 1994. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human xenograft. Cancer Res. 54, 3352-3356.
71. Zuidam, N.J., Lee, S.S., Crommelin, D.J., 1995. Gamma-irradiation of non-frozen, frozen, and freeze-dried liposomes. Pharm Res. 12, 1761-1768.
72. Zuidam, N.J., Lee, S.S., Crommelin, D.J., 1993. Sterilization of liposomes by heat treatment. Pharm. Res. 10, 1591-1596.